Market Snapshot

S&P Futures
4,402.75
Dow Futures
34,948.00
NASDAQ Futures
15,095.50

4.31$-1.03 -19.29%
Market open    14:09:16 pm   
From: To:

Stock Snapshot

3.21
Prev. Close
4.01
Open
88.35M
Market Cap
2.44M
Number of Shares
4.2500
Day Low
7.3400
Day High
4.31
-
P/E Ratio
18.55M
Free Float in %
-1.27
EPS 2021
1.15
Book Value per Share
0.70
Cash Flow per Share
Chembio Diagnostics, Inc. (CEMI)
Chembio Diagnostics, Inc. (CEMI) stock rallied over -19.29% intraday to trade at $4.31 per share on NASDAQ. The stock opened with a gain of 24.92% at $4.01 and touched an intraday high of $7.3400, rising 128.66% against the last close of $3.21. The stock went to a low of $4.2500 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-07-01$2.98$2.91$2.91$3.01$2.89302,018
2021-06-30$3.02$2.97$2.97$3.04$2.94394,300
2021-06-29$3.12$3.02$3.02$3.13$2.99415,600
2021-06-28$3.18$3.11$3.11$3.25$3.08513,400
2021-06-25$3.05$3.15$3.15$3.21$3.053,041,100
2021-06-24$3.00$3.09$3.09$3.10$2.97477,000
2021-06-23$2.90$3.02$3.02$3.02$2.90376,700
2021-06-22$2.90$2.88$2.88$2.95$2.81466,800
2021-06-21$3.02$2.90$2.90$3.04$2.83725,700
2021-06-18$3.06$3.03$3.03$3.09$3.01492,100
2021-06-17$3.07$3.07$3.07$3.14$3.05412,100
Chembio Diagnostics, Inc.
555 Wireless Boulevard
Hauppauge, NY 11788
United States

http://chembio.com
631 924 1135
Employees
355
Sector
Healthcare
Sales or Revenue
Industry
Diagnostics & Research
5Y Sales Change
6.00
Fiscal Year Ends
2020-12-30
Mr. Neil A. Goldman
Exec. VP & CFO
Mr. Javan Esfandiari
Exec. VP, Chief Science & Technology Officer
Mr. Richard L. Eberly
Pres, CEO & Director
Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam